Publications by authors named "Karlijn de Joode"

Claim this Profile
R
Response to letter Re: Impact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitors.
Asli Özkan, Karlijn de Joode, Ellen Kapiteijn, Marije Slingerland, Stephanie Zunder

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of geriatric impairments on outcomes of single-agent immunotherapy in solid tumors.
Asli Özkan, Karlijn de Joode, Ellen Kapiteijn, Marije Slingerland, Stephanie Zunder

Int J Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter Re: Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial.
Brigit van Dijk, Joséphine C Janssen, Evalyn E A P Mulder, Karlijn de Joode, Astrid A M van der Veldt

Eur J Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitors.
Asli Özkan, Karlijn de Joode, Ellen Kapiteijn, Marije Slingerland, Stephanie Zunder

Eur J Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.
Karlijn de Joode, Alfonso Rojas Mora, Ron H N van Schaik, Alfred Zippelius, Astrid van der Veldt

J Immunother· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
Lindsay V M Leek, Jessica C L Notohardjo, Karlijn de Joode, Eline L Velker, John B A G Haanen

Sci Rep· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From decision to reflection: understanding the experiences and unmet care needs of patients treated with immunotherapy for melanoma in the adjuvant or metastatic setting.
Nadia C W Kamminga, Astrid A M van der Veldt, Marlies Wakkee, Fauve R van den Berge, Lianne A A van der Beek, Karlijn de Joode

BMC Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review - The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors.
Karlijn de Joode, Niels Heersche, Edwin A Basak, Sander Bins, Astrid A M van der Veldt

Cancer Treat Rev· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report.
Karlijn de Joode, Sharon Veenbergen, Claudia Kransse, Dian Kortleve, Reno Debets

J Immunother Cancer· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy.
Edwin A Basak, Karlijn de Joode, Tom J J Uyl, Ronald van der Wal, Marco W J Schreurs

Biomed Pharmacother· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study.
Edwin A Basak, Niels S Vermeer, Karlijn de Joode, Daan P Hurkmans, Dorian E M Velthuis

Eur J Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma.
Nadia C W Kamminga, Astrid A M van der Veldt, Margot C W Joosen, Karlijn de Joode, Arjen Joosse

Br J Dermatol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients with primary brain tumors and COVID-19: A report from the Dutch Oncology COVID-19 Consortium.
Karlijn de Joode, Walter Taal, Tom J Snijders, Monique Hanse, Johan A F Koekkoek

Neuro Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium.
Karlijn de Joode, Jolien Tol, Paul Hamberg, Marissa Cloos, Elisabeth A Kastelijn

Eur J Cancer· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.
Judith M Versluis, Anne M Hendriks, Alison M Weppler, Lauren J Brown, Karlijn de Joode

Eur J Cancer· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors.
Daan P Hurkmans, Sebastiaan D T Sassen, Karlijn de Joode, Lisanne Putter, Edwin A Basak

J Immunother Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remarkable Healthy Cohort of Patients With Cancer.
Karlijn de Joode, Anne-Marie C Dingemans, Astrid A M van der Veldt

J Clin Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study.
Karlijn de Joode, Daphne W Dumoulin, Jolien Tol, Hans M Westgeest, Laurens V Beerepoot

Eur J Cancer· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab plus ipilimumab as neoadjuvant treatment in primary advanced renal cell tumors: Cutting edges for cutting-edge surgery.
Karlijn de Joode, Jolanda I de Ruig-Spakman, Sarwan S Baktawar, Geert J L H van Leenders, Paul C M S Verhagen

Urol Oncol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: Laurence Albiges, Tom Powles, Michael Staehler, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-Cell Renal Cell Carcinoma. Eur Urol 2019;76:151-6: Active Surveillance in Metastatic Renal Cell Cancer: Missing a Chance for Cure?
Karlijn de Joode, Astrid A M van der Veldt

Eur Urol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis